Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction Adenocarcinoma
CompletedOBSERVATIONAL
Enrollment
120
Participants
Timeline
Start Date
January 1, 2021
Primary Completion Date
June 1, 2022
Study Completion Date
December 30, 2022
Conditions
Immune-related Adverse EventChemotherapeutic ToxicityGastric or Gastroesophageal Junction Adenocarcinoma